Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer Study

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer Study - ONCO DVT Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051190010

Enrollment

600

Registered

2019-04-24

Start date

2019-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis Deep vein thrombosis

Interventions

Three months of Edoxaban treatment g roup (Short DOAC group) and 12 months of Edoxaban treatment group (Long DOAC group)

Anticoagulants

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with newly found isolated distal deep vein thrombosis complicated with active cancer who are scheduled to be treated by anticoagulation therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with anticoag ulation therapy for the Index event before 10 days of allocation. 2. Patient under anticoag ulation therapy for the purpose of other than the Index event. 3. Patients with thrombolysis therapy or IVC filter at the Index event. 4. Patients with creatinine clearance less than 30 ml/min. 5. Patients who are expected to have a life prognosis of 3 months or less. 6. Patients with pulmonary embolism. 7. Patients who are not appropriate for the participation of the study.

Design outcomes

Primary

Measure	Time frame
Symptomatic VTE recurrence event / VTE related death event at 12 months.	—

Secondary

Measure	Time frame
Major bleeding event (ISTH criteria) at 12 months.	—

Contacts

Public ContactYugo Yamashita

Graduate School of Medicine, Kyoto University

yyamashi@kuhp.kyoto-u.ac.jp+81-75-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026